These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8032880)

  • 1. Lasting effects of dopamine receptor agonists upon striatal dopamine release in free-moving rats: an in vivo voltammetric study.
    Abraini JH; Fechtali T; Rostain JC
    Brain Res; 1994 Apr; 642(1-2):199-205. PubMed ID: 8032880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dopamine D-1 and D-2 receptor selective drugs on dopamine release and metabolism in rat striatum in vivo.
    Zetterström T; Sharp T; Ungerstedt U
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Oct; 334(2):117-24. PubMed ID: 2946964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D1 receptors modulate striatal dopamine release induced by the stimulation of both D1 and D2 receptors: in vivo voltammetric data revisited.
    Fechtali T; Issoual D; Abraini JH
    J Physiol Paris; 1994; 88(5):331-3. PubMed ID: 7787831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pressure reversed extracellular striatal dopamine decrease produced by D1 receptor agonist SKF 38393, and D2 receptor agonist LY 171555, but failed to change the effect of the activation of both D1 and D2 receptors.
    Abraini JH; Fechtali T; Rostain JC
    Neuroscience; 1992 Sep; 50(2):395-402. PubMed ID: 1359460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
    Pollack AE; Wooten GF
    Brain Res Mol Brain Res; 1992 Jan; 12(1-3):111-9. PubMed ID: 1312196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.
    DeBoer P; Abercrombie ED
    J Pharmacol Exp Ther; 1996 May; 277(2):775-83. PubMed ID: 8627558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of acetylcholine release by D1, D2 dopamine receptors in rat striatum under freely moving conditions.
    Ajima A; Yamaguchi T; Kato T
    Brain Res; 1990 Jun; 518(1-2):193-8. PubMed ID: 1975213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.
    Jiang HK; McGinty JF; Hong JS
    Brain Res; 1990 Jan; 507(1):57-64. PubMed ID: 1967976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biphasic effect of locally applied apomorphine and 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine on the release of striatal dopamine investigated by means of brain dialysis.
    Kurata K; Shibata R
    Neurosci Lett; 1990 Sep; 117(3):264-8. PubMed ID: 1982738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity.
    LaHoste GJ; Yu J; Marshall JF
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7451-5. PubMed ID: 8102797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo assessment of release and metabolism of dopamine in the ventrolateral striatum of awake rats following administration of dopamine D1 and D2 receptor agonists and antagonists.
    See RE; Sorg BA; Chapman MA; Kalivas PW
    Neuropharmacology; 1991 Dec; 30(12A):1269-74. PubMed ID: 1686300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors.
    Santiago M; Westerink BH
    Eur J Pharmacol; 1991 Oct; 204(1):79-85. PubMed ID: 1687125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems.
    Singh NA; Bush LG; Gibb JW; Hanson GR
    Brain Res; 1992 Feb; 571(2):260-4. PubMed ID: 1351780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation.
    Thomas KL; Rose S; Jenner P; Marsden CD
    Biochem Pharmacol; 1992 Jul; 44(1):73-82. PubMed ID: 1321630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The D1 agonist SKF 38393 increases dopamine release in the developing rat striatum.
    Walters DE; Howard SG
    Eur J Pharmacol; 1990 Aug; 184(2-3):257-64. PubMed ID: 2150376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.